Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06646276 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06646276 · ClinicalTrials.gov record · last posted 2026-08-14

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

StatusRecruiting
PhasePhase 3
Started2025-02-25
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as First-Line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer.

Amendment record 31 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 31 times since 2024-10-16; most recent amendment 2026-07-17. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2025-01-28
Status change Not Yet Recruiting→Recruitingv3
Trial Details
NCT Number NCT06646276
Lead Sponsor Bristol-Myers Squibb
Conditions Extensive-Stage Small Cell Lung Cancer
Enrollment 530 participants
Start Date 2025-02-25
Primary Completion 2028-04-06 (estimated)
Study Completion 2031-09-05 (estimated)
Updated on ClinicalTrials.gov 2026-08-14